Autologous and allogeneic bone grafts are considered the gold standard when it comes to reconstructing bones, largely due to their bioactive compounds and osteoblastic cells that can generate new bone effectively. However, limited supply, donor-site complications, and risk of disease transmission have deterred its widespread use.